Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, John P. Neoptolemos, Angus Robinson et al.|The Lancet Oncology|2014Cited by 374
Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast CancerAbigail Shea, Alejandra Bruna, Yaniv Lubling et al.|Cancer Research|2024Cited by 7
Data from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast CancerAbigail Shea, Alejandra Bruna, Yaniv Lubling et al.|Unknown|2025Cited by 1
Figure 6 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast CancerAbigail Shea, Alejandra Bruna, Yaniv Lubling et al.|Unknown|2025Cited by 0
Figure 5 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast CancerAbigail Shea, Alejandra Bruna, Yaniv Lubling et al.|Unknown|2025Cited by 0